# OrigAMI-5 (NCT07276399)

> A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07276399
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Squamous Cell Carcinoma of Head and Neck
- Interventions: Amivantamab; Pembrolizumab; Carboplatin; 5-Flurouracil; Cisplatin
- Enrollment: 500
- Primary outcome: Overall Survival (OS)
- Primary outcome: Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

## Commentary we found

- YouTube: 10
- Podcasts: 4
- X threads: 3
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=origami-5-nct07276399

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07276399", "email": "<work email>"}; the inbox owner confirms by the emailed link.